Scott M. Wasserman
CIK: 0002118767
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Oct 19, 2026IKT
Inhibikase Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
310K shares- - Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
100K shares- - Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
100K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 19, 2026 |  IKT Inhibikase Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 310,000 | - | - | Direct |
| Apr 16, 2026 |  KLRA Kailera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
1-3 of 3 transactions
About Wasserman Scott M.
Wasserman Scott M. (SEC CIK 0002118767) files insider reports with the SEC as Director of Inhibikase Therapeutics, Inc. (IKT) and Chief Medical Officer of Kailera Therapeutics, Inc. (KLRA).
Signal8 holds 4 ownership filings by Wasserman Scott M. (2 Form 3, 2 Form 4), filed between Apr 16, 2026 and Oct 21, 2026. Those filings report 3 transactions, from Apr 16, 2026 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wasserman Scott M.'s filings is in WILMINGTON, DE.
Recent filings by Wasserman Scott M.
Other insiders filing for Inhibikase Therapeutics, Inc. (IKT)
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- Aurentz Vincent, Director
- Cabell Christopher, President & Head of R&D
- Munshi Amit, Director
- Iwicki Mark T, Chief Executive Officer
- McIntyre David, Chief Financial Officer